Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
University of California, San Francisco
University of California, San Francisco
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Incyte Corporation
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Qilu Pharmaceutical Co., Ltd.
OHSU Knight Cancer Institute
National Cancer Institute (NCI)
National Cancer Institute (NCI)
AstraZeneca
OHSU Knight Cancer Institute
MOMA Therapeutics
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Nuvation Bio Inc.
Cambridge University Hospitals NHS Foundation Trust
Exelixis
AstraZeneca
Australasian Gastro-Intestinal Trials Group
University of Colorado, Denver
Georgetown University
Asan Medical Center
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
M.D. Anderson Cancer Center
Tango Therapeutics, Inc.
University Health Network, Toronto
Azienda Ospedaliero-Universitaria di Modena
Seoul National University Hospital
Seoul National University Hospital
AstraZeneca
OHSU Knight Cancer Institute
OHSU Knight Cancer Institute
Academic and Community Cancer Research United
AstraZeneca
Yale University
Canadian Cancer Trials Group
AstraZeneca
Ellipses Pharma
Sheba Medical Center
Grupo Espanol Multidisciplinario del Cancer Digestivo
AstraZeneca
Royal Marsden NHS Foundation Trust
AstraZeneca
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
AstraZeneca
The Christie NHS Foundation Trust